
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Hereditary Colorectal Polyposis and Cancer Syndromes: A Primer on Diagnosis and Management  </title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>Hereditary Colorectal Polyposis and Cancer Syndromes: A Primer on Diagnosis and Management  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: <em>The American Journal of Gastroenterology</em> 2017;112:1509‑1525  </li>
<li style="margin-left: 0px;">Authors: N.J. Samadder, P. Kanth, R.W. Burt, J. Grimmett, M. Champine, N.J. Samadder  </li>
</ul>
<details><summary><strong>1. Epidemiology &amp; Clinical Context  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">CRC = 3ᵗʰ most common cancer, 2ⁿᵈ leading cause of death in US men &amp; women.  </li>
<li style="margin-left: 0px;">Hereditary CRC ≈ 5 % of all CRCs (mutations/defects in specific genes).  </li>
<li style="margin-left: 0px;">Familial CRC without known genetics ≈ 25‑30 % of patients.  </li>
<li style="margin-left: 0px;">High‑risk hereditary syndromes → 70‑100 % lifetime CRC risk; many also ↑ extra‑intestinal malignancies.  </li>
<li style="margin-left: 0px;">Patients with pathogenic mutations require <strong>intensified surveillance</strong> &amp; comprehensive management vs. average‑risk population.  </li>
<li style="margin-left: 0px;">Genetic counseling is essential for risk communication and care coordination.  </li>
</ul>
</div></details>
<details><summary><strong>2. Lynch Syndrome (LS) – Overview  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>2.1 Prevalence &amp; Cancer Risks  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">LS accounts for ~2‑4 % of all CRCs; most common hereditary colon cancer.  </li>
<li style="margin-left: 0px;">Lifetime CRC risk: <strong>50‑80 %</strong>; endometrial cancer risk: <strong>40‑60 %</strong>.  </li>
<li style="margin-left: 0px;">Overall prevalence ≈ 1 in 440 individuals.  </li>
<li style="margin-left: 0px;">Extra‑colonic cancers &amp; approximate lifetime risks (95 % CI):  </li>
</ul>
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Organ</th>
<th>LS Gene(s)</th>
<th>Lifetime Risk % (95 % CI)</th>
</tr></thead>
<tbody>
<tr>
<td>Colon/Rectum</td>
<td>MLH1, MSH2, MSH6, PMS2, EPCAM</td>
<td>15‑52 (varies by gene)</td>
</tr>
<tr>
<td>Endometrium</td>
<td>MLH1, MSH2, MSH6, PMS2</td>
<td>21‑57</td>
</tr>
<tr>
<td>Stomach</td>
<td>MLH1, MSH2</td>
<td>11‑19</td>
</tr>
<tr>
<td>Ovary</td>
<td>MSH2, MSH6, PMS2</td>
<td>1‑38</td>
</tr>
<tr>
<td>Hepatobiliary</td>
<td>All LS genes</td>
<td>2‑7</td>
</tr>
<tr>
<td>Upper urinary tract</td>
<td>All LS genes</td>
<td>4‑5</td>
</tr>
<tr>
<td>Pancreas</td>
<td>All LS genes</td>
<td>3‑4</td>
</tr>
<tr>
<td>Small bowel</td>
<td>All LS genes</td>
<td>1‑4</td>
</tr>
<tr>
<td>CNS (glioblastoma)</td>
<td>All LS genes</td>
<td>1‑3</td>
</tr>
</tbody>
</table>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Gene‑specific risk hierarchy: <strong>MLH1/MSH2</strong> &gt; <strong>MSH6</strong> ≈ <strong>PMS2</strong>.  </li>
</ul>
</div></details>
<details><summary><strong>2.2 Genetics &amp; Molecular Pathogenesis  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Autosomal dominant disorder of DNA mismatch repair (MMR).  </li>
<li style="margin-left: 0px;">Causative genes: <strong>MLH1, MSH2, MSH6, PMS2, EPCAM</strong> (deletion → silencing of MSH2).  </li>
<li style="margin-left: 0px;">MMR function: correct single‑nucleotide mismatches, insertion/deletion loops during replication.  </li>
<li style="margin-left: 0px;">Mutation distribution: MLH1/MSH2 ≈ 70 % of LS; MSH6 ≈ 14 %; PMS2 &lt; 15 %.  </li>
</ul>
</div></details>
<details><summary><strong>2.3 Diagnostic Criteria &amp; Testing Strategy  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Amsterdam I</strong>: ≥3 first‑degree relatives with CRC, spanning ≥2 generations, ≥1 diagnosed &lt;50 y, FAP excluded, pathology confirmed.  </li>
<li style="margin-left: 0px;"><strong>Amsterdam II</strong>: Same as I but includes LS‑related extra‑colonic cancers.  </li>
<li style="margin-left: 0px;"><strong>Revised Bethesda</strong> (tumor‑based): MSI testing or IHC indicated when any of the following:  </li>
</ul>
<p>a) CRC diagnosed &lt;50 y;</p>
<p>b) Synchronous/metachronous LS‑associated tumors regardless of age;</p>
<p>c) CRC with MSI‑high histology diagnosed &lt;60 y;</p>
<p>d) CRC + ≥1 first‑degree relative with LS cancer ≤50 y;</p>
<p>e) CRC + ≥2 first/second‑degree relatives with LS cancers any age.</p>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Tumor testing</strong>: Immunohistochemistry (IHC) for MLH1, MSH2, MSH6, PMS2; MSI analysis. Absent protein → targeted germline testing of corresponding gene.  </li>
<li style="margin-left: 0px;"><strong>Germline testing algorithm</strong>:  </li>
<li style="margin-left: 20px;">If IHC abnormal → sequence the absent‑protein gene.  </li>
<li style="margin-left: 20px;">If MLH1 loss → reflex to BRAF V600E mutation or MLH1 promoter methylation to distinguish sporadic vs LS.  </li>
<li style="margin-left: 0px;"><strong>Predictive models</strong> (risk calculators): PREMM 1,2,6; MMRpro; MMRpredict – incorporate personal &amp; family cancer history.  </li>
</ul>
</div></details>
<details><summary><strong>2.4 Surveillance Recommendations (NCCN)  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Modality</th>
<th>Initiation Age</th>
<th>Interval</th>
</tr></thead>
<tbody>
<tr>
<td>Colonoscopy</td>
<td>20‑25 y (or 10 y before earliest CRC in family)</td>
<td>Every <strong>1‑2 y</strong></td>
</tr>
<tr>
<td>Upper endoscopy (gastric &amp; duodenal)</td>
<td>30‑35 y</td>
<td>Every <strong>3‑5 y</strong> (consider earlier if family gastric cancer)</td>
</tr>
<tr>
<td>Endometrial sampling + transvaginal US (women)</td>
<td>After childbearing completion</td>
<td>Consider prophylactic hysterectomy ± BSO; otherwise annual or per protocol.</td>
</tr>
<tr>
<td>Other organ surveillance (e.g., pancreas, urinary tract) – individualized based on family history &amp; gene‑specific risk.</td>
</tr>
</tbody>
</table>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Prophylactic <strong>hysterectomy + bilateral salpingo‑oophorectomy</strong> after childbearing for women with LS (especially MLH1/MSH2 carriers).  </li>
</ul>
</div></details>
<details><summary><strong>2.5 Chemoprevention Evidence  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Aspirin</strong>: CAPP2 trial – ≥2 y daily aspirin (600 mg) → 63 % ↓ CRC incidence (IRR 0.37, 95 % CI 0.18‑0.78). Benefit persists despite obesity; dose–response unclear.  </li>
<li style="margin-left: 0px;">USPSTF “B” recommendation for low‑dose aspirin (81‑300 mg) in adults 50‑59 y with ≥10 % 10‑yr CVD risk – many LS patients qualify.  </li>
<li style="margin-left: 0px;">Bleeding risks: ↑ hemorrhagic stroke 32‑36 %; GI bleed 30‑70 % vs baseline; balance individualized.  </li>
</ul>
</div></details>
<details><summary><strong>2.6 Emerging &amp; Adjunctive Strategies  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Universal tumor screening</strong> for all CRC (MSI/IHC) – cost‑effective in identifying LS families.  </li>
<li style="margin-left: 0px;">Multi‑gene NGS panels (“panels”) increasingly used; interpretation complexity ↑ (VUS, incidental findings).  </li>
<li style="margin-left: 0px;">Ongoing trials: dose‑finding aspirin studies (CAAPP3), combination NSAID/EGFR inhibitor regimens for duodenal adenomas.  </li>
</ul>
<p><em>End of Part 1 – covering epidemiology, Lynch syndrome overview, genetics, diagnosis, surveillance, and chemoprevention.</em></p>
</div></details>
</div></details>
<details><summary><strong>3. Familial Adenomatous Polyposis (FAP) &amp; Attenuated FAP (AFAP)  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>3.1 Overview &amp; Cancer Risks  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Classic FAP: <strong>≥100 %</strong> lifetime CRC risk if untreated; polyps appear teens.  </li>
<li style="margin-left: 0px;">AFAP: <strong>70 %</strong> CRC risk; fewer polyps (10‑100), later onset (&gt;25 y).  </li>
<li style="margin-left: 0px;">Extra‑colonic malignancies: duodenal/periampullary cancer <strong>4‑12 %</strong>, thyroid carcinoma ~2 %, desmoid tumors up to 20 %.  </li>
</ul>
</div></details>
<details><summary><strong>3.2 Genetics &amp; Molecular Basis  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Autosomal dominant APC gene mutation (tumor suppressor, WNT pathway).  </li>
<li style="margin-left: 0px;">EPCAM deletions not implicated in FAP.  </li>
<li style="margin-left: 0px;"><strong>Mutation hotspots:</strong> codons 1309‑1324 (classic), 5′/3′ regions (AFAP).  </li>
<li style="margin-left: 0px;">~25‑30 % de novo APC mutations → family history may be absent.  </li>
</ul>
</div></details>
<details><summary><strong>3.3 Diagnostic Criteria &amp; Testing  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Clinical suspicion: hundreds–thousands of adenomatous polyps on colonoscopy.  </li>
<li style="margin-left: 0px;">Germline APC testing indicated when:  </li>
<li style="margin-left: 20px;">&gt;10 cumulative adenomas in a single exam, <strong>or</strong>  </li>
<li style="margin-left: 20px;">≥10 adenomas + personal CRC history, <strong>or</strong>  </li>
<li style="margin-left: 20px;">Lifetime &gt;20 adenomas.  </li>
<li style="margin-left: 0px;">~10‑30 % of clinically diagnosed FAP/AFAP lack identifiable APC mutation → consider deep intronic variants, large deletions, mosaicism, or other genes (POLE, POLD1, GREM1).  </li>
</ul>
</div></details>
<details><summary><strong>3.4 Surveillance &amp; Management  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>3.4.1 Colonoscopic Surveillance  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Initiate colonoscopy <strong>10‑12 y</strong> (classic) or <strong>20‑25 y</strong> (AFAP).  </li>
<li style="margin-left: 0px;">Interval: <strong>annual</strong> for classic FAP; <strong>every 1‑2 y</strong> for AFAP if polyp burden manageable.  </li>
</ul>
</div></details>
<details><summary><strong>3.4.2 Surgical Intervention  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Indications: polyps &gt;1 cm, advanced histology, or burden unmanageable endoscopically (often &gt;20).  </li>
<li style="margin-left: 0px;">Options:  </li>
<li style="margin-left: 20px;"><strong>Total colectomy with ileorectal anastomosis (IRA)</strong> – preserves rectum; risk of rectal cancer → annual rectal surveillance.  </li>
<li style="margin-left: 20px;"><strong>Proctocolectomy with ileal‑pouch‑anal anastomosis (IPAA)</strong> – eliminates rectal reservoir; lower rectal cancer risk but higher pouch adenoma prevalence.  </li>
<li style="margin-left: 0px;">Comparative outcomes: IPAA shows improved long‑term survival vs. IRA; similar postoperative complication rates.  </li>
</ul>
</div></details>
<details><summary><strong>3.4.3 Upper GI &amp; Duodenal Surveillance  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Begin <strong>age 25‑30 y</strong>; upper endoscopy every <strong>1‑3 y</strong> (Spigelman staging).  </li>
<li style="margin-left: 0px;">Spigelman points: number, size, histology, dysplasia → stage 0‑IV; surveillance interval ranges from every 4 y (stage 0) to every 6‑12 m (stage III/IV).  </li>
</ul>
</div></details>
<details><summary><strong>3.4.4 Extra‑Colonic Cancer Screening  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Thyroid ultrasound</strong> annually starting late teens (risk ~2 %).  </li>
<li style="margin-left: 0px;"><strong>Desmoid tumor monitoring:</strong> clinical exam; MRI if symptomatic.  </li>
<li style="margin-left: 0px;"><strong>Hepatoblastoma screening</strong> in children ≤5 y: AFP + liver US every 3‑6 m (rare).  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>3.5 Chemoprevention in FAP  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Sulindac</strong> (150 mg BID) → ↓ adenoma count ~56 % and size ~65 %; effect reversible after discontinuation.  </li>
<li style="margin-left: 0px;"><strong>Celecoxib</strong> (400 mg BID) shows adenoma regression at higher doses; FDA indication withdrawn for FAP.  </li>
<li style="margin-left: 0px;">Combination sulindac + erlotinib trial: 71 % ↓ duodenal polyp burden after 6 m; acne‑like rash common.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>4. MUTYH‑Associated Polyposis (MAP)  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>4.1 Overview &amp; Epidemiology  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Autosomal recessive biallelic MUTYH mutations → <strong>≈80 %</strong> lifetime CRC risk.  </li>
<li style="margin-left: 0px;">Typical phenotype: 15‑100 adenomas, often resembling AFAP; may include serrated polyps.  </li>
</ul>
</div></details>
<details><summary><strong>4.2 Genetics &amp; Pathophysiology  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">MUTYH encodes base‑excision repair enzyme correcting oxidative DNA damage (8‑oxoguanine).  </li>
<li style="margin-left: 0px;">Most common pathogenic variants: <strong>Y179C</strong> and <strong>G396D</strong>.  </li>
<li style="margin-left: 0px;">Monoallelic carriers have minimal CRC risk unless strong family history.  </li>
</ul>
</div></details>
<details><summary><strong>4.3 Diagnostic Approach  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Indications for MUTYH testing:  </li>
<li style="margin-left: 20px;">≥10 adenomas without APC mutation, <strong>or</strong>  </li>
<li style="margin-left: 20px;">Multiple serrated polyps + adenomas, <strong>or</strong>  </li>
<li style="margin-left: 20px;">Family history suggestive of recessive inheritance.  </li>
<li style="margin-left: 0px;">Biallelic confirmation required for MAP diagnosis; heterozygous results reported separately.  </li>
</ul>
</div></details>
<details><summary><strong>4.4 Surveillance &amp; Management  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>4.4.1 Colonoscopic Protocol  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Initiate colonoscopy <strong>25‑30 y</strong>; repeat every <strong>2‑3 y</strong> if negative, <strong>1‑2 y</strong> if polyps detected.  </li>
<li style="margin-left: 0px;">Monoallelic carriers: consider colonoscopy at <strong>40 y</strong>, interval <strong>5 y</strong> (adjust per family history).  </li>
</ul>
</div></details>
<details><summary><strong>4.4.2 Upper GI Surveillance  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Baseline upper endoscopy <strong>30‑35 y</strong>; repeat based on duodenal findings (similar Spigelman criteria as FAP).  </li>
</ul>
</div></details>
<details><summary><strong>4.4.3 Extra‑Colonic Cancer Risks  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">↑ risk of pancreatic, ovarian, bladder, skin cancers (reported but no formal screening guidelines).  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>4.5 Chemoprevention &amp; Therapeutics  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Limited data; NSAIDs (sulindac) may reduce adenoma burden, but evidence weaker than in FAP.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>5. Hamartomatous Polyposis Syndromes  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>5.1 Peutz‑Jeghers Syndrome (PJS)  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>5.1.1 Clinical Features &amp; Cancer Risks  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>STK11/LKB1</strong> germline mutation (≈50‑70 % of cases).  </li>
<li style="margin-left: 0px;">Characteristic mucocutaneous melanin macules (mouth, lips, perioral, genitalia).  </li>
<li style="margin-left: 0px;">GI hamartomatous polyps → intussusception risk.  </li>
<li style="margin-left: 0px;">Lifetime cancer risks: colorectal 39 %, pancreatic 11‑36 %, breast 54 %, gynecologic (ovarian 21 %, cervical) ~15‑20 %, gastric 29 %, lung 15 %.  </li>
</ul>
</div></details>
<details><summary><strong>5.1.2 Surveillance Recommendations  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Modality</th>
<th>Start Age</th>
<th>Frequency</th>
</tr></thead>
<tbody>
<tr>
<td>Colonoscopy &amp; upper endoscopy</td>
<td>Late teens</td>
<td>Every <strong>2‑3 y</strong> (if normal)</td>
</tr>
<tr>
<td>Small bowel imaging (CT/MR enterography, capsule)</td>
<td>8‑10 y</td>
<td>Every <strong>1‑3 y</strong></td>
</tr>
<tr>
<td>Pancreatic MRI/EUS</td>
<td>25‑30 y</td>
<td>Every <strong>1‑2 y</strong></td>
</tr>
<tr>
<td>Breast MRI &amp; mammogram</td>
<td>25‑30 y</td>
<td>Annually</td>
</tr>
<tr>
<td>Gynecologic exam + PAP</td>
<td>18‑20 y</td>
<td>Annually; consider transvaginal US</td>
</tr>
<tr>
<td>Testicular US (males)</td>
<td>10 y</td>
<td>Annually</td>
</tr>
</tbody>
</table>
</div></details>
<details><summary><strong>5.1.3 Management of Complications  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Endoscopic polypectomy for symptomatic polyps; surgical resection for recurrent intussusception.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>5.2 Juvenile Polyposis Syndrome (JPS)  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>5.2.1 Genetics &amp; Phenotype  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>SMAD4</strong> or <strong>BMPR1A</strong> mutations (~50 % of cases).  </li>
<li style="margin-left: 0px;">≥3–5 juvenile polyps in colon/rectum, often large, pedunculated; histology: inflamed lamina propria, mucin‑filled cystic glands.  </li>
</ul>
</div></details>
<details><summary><strong>5.2.2 Cancer Risks &amp; Surveillance  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">CRC risk ≈ 39 %; gastric cancer risk modest but reported.  </li>
<li style="margin-left: 0px;">Colonoscopy start <strong>15 y</strong>, repeat annually if polyps present, otherwise every <strong>2‑3 y</strong>.  </li>
<li style="margin-left: 0px;">Upper endoscopy start <strong>15 y</strong>, interval <strong>1‑3 y</strong> based on findings.  </li>
</ul>
</div></details>
<details><summary><strong>5.2.3 Overlap with Hereditary Hemorrhagic Telangiectasia (HHT)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">SMAD4 mutation carriers may exhibit HHT features (telangiectasias, AVMs).  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>5.3 PTEN Hamartoma Tumor Syndrome (PHTS) / Cowden Syndrome (CS)  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>5.3.1 Genetics &amp; Clinical Spectrum  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Germline <strong>PTEN</strong> loss‑of‑function; autosomal dominant.  </li>
<li style="margin-left: 0px;">Features: multiple hamartomatous polyps (colon, stomach, small bowel), macrocephaly, mucocutaneous lesions (trichilemmomas, papillomas).  </li>
</ul>
</div></details>
<details><summary><strong>5.3.2 Cancer Risks &amp; Screening  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Organ</th>
<th>Lifetime Risk %</th>
</tr></thead>
<tbody>
<tr>
<td>Breast (female)</td>
<td>54 %</td>
</tr>
<tr>
<td>Endometrium (epithelial)</td>
<td>↑ (data variable)</td>
</tr>
<tr>
<td>Thyroid (follicular)</td>
<td>~10‑15 %</td>
</tr>
<tr>
<td>Colon</td>
<td>9‑18 %</td>
</tr>
<tr>
<td>Renal cell carcinoma</td>
<td>≤5 %</td>
</tr>
<tr>
<td>Others (skin, CNS)</td>
<td>Low‑moderate</td>
</tr>
</tbody>
</table>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Colonoscopy</strong> start <strong>35 y</strong> (or 5‑10 y before earliest CRC in family).  </li>
<li style="margin-left: 0px;"><strong>Breast MRI/mammogram</strong> annually from <strong>30‑35 y</strong>.  </li>
<li style="margin-left: 0px;"><strong>Thyroid US</strong> annually from diagnosis.  </li>
</ul>
</div></details>
<details><summary><strong>5.3.3 Diagnostic Criteria (PTEN)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Major: macrocephaly, Lhermitte‑Duclos disease, GI hamartomas, breast cancer, endometrial carcinoma, thyroid cancer, mucocutaneous lesions.  </li>
<li style="margin-left: 0px;">Minor: autism spectrum disorder, colon cancer, esophageal glycogenic acanthosis, lipomas, renal cell carcinoma, etc.  </li>
</ul>
</div></details>
</div></details>
</div></details>
<details><summary><strong>6. Serrated Polyposis Syndrome (SPS)  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>6.1 Definition &amp; Diagnostic Criteria (WHO)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Criterion A:</strong> ≥5 serrated polyps proximal to sigmoid, ≥2 &gt;10 mm.  </li>
<li style="margin-left: 0px;"><strong>Criterion B:</strong> Any number of serrated polyps throughout colon + first‑degree relative with SPS.  </li>
<li style="margin-left: 0px;"><strong>Criterion C:</strong> &gt;20 serrated polyps of any size distributed throughout colon.  </li>
</ul>
</div></details>
<details><summary><strong>6.2 Epidemiology &amp; Cancer Risk  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Prevalence in screening cohorts: 0–0.5 % (initial colonoscopy) up to 0.8 % on repeat exams.  </li>
<li style="margin-left: 0px;">Lifetime CRC risk <strong>16‑42 %</strong>; advanced adenoma prevalence 9‑34 %.  </li>
</ul>
</div></details>
<details><summary><strong>6.3 Surveillance &amp; Management  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Colonoscopy every <strong>1‑3 y</strong> (some guidelines advocate annual).  </li>
<li style="margin-left: 0px;">Remove all serrated lesions ≥5 mm; consider chromoendoscopy for detection.  </li>
<li style="margin-left: 0px;">No specific extra‑colonic screening; follow general population recommendations unless family history dictates earlier initiation.  </li>
</ul>
</div></details>
<details><summary><strong>6.4 Genetic Landscape &amp; Testing  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">No single causative gene identified; occasional overlap with <strong>MUTYH</strong> or <strong>MMR</strong> mutations.  </li>
<li style="margin-left: 0px;">MSI, CpG island methylator phenotype (CIMP), and BRAF V600E frequently observed in serrated pathway lesions.  </li>
</ul>
<p><em>End of Part 2 – covering FAP/AFAP, MAP, hamartomatous polyposis syndromes (PJS, JPS, PHTS), and Serrated Polyposis Syndrome.</em></p>
</div></details>
</div></details>
<details><summary><strong>7. Genetic Counseling &amp; Risk Assessment  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>7.1 Role of the Genetics Counselor  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Provides <strong>comprehensive cancer‑family history</strong> collection (≥3 generations).  </li>
<li style="margin-left: 0px;">Interprets pedigree using <strong>Amsterdam</strong>, <strong>Bethesda</strong>, and <strong>NCCN</strong> criteria.  </li>
<li style="margin-left: 0px;">Discusses <strong>inheritance patterns</strong>, penetrance, variable expressivity, and psychosocial implications.  </li>
<li style="margin-left: 0px;">Facilitates informed consent for germline testing; explains <strong>variant of uncertain significance (VUS)</strong> handling.  </li>
</ul>
</div></details>
<details><summary><strong>7.2 Pre‑test Counseling Elements  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Indications for testing (clinical criteria, predictive models).  </li>
<li style="margin-left: 0px;">Potential outcomes: pathogenic mutation, VUS, negative result.  </li>
<li style="margin-left: 0px;">Implications for <strong>insurance</strong>, employment, and family planning (e.g., prenatal or preimplantation genetic diagnosis).  </li>
</ul>
</div></details>
<details><summary><strong>7.3 Post‑test Follow‑up  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Positive result → cascade testing of at‑risk relatives (first‑degree ≥50 % risk).  </li>
<li style="margin-left: 0px;">Negative result in high‑clinical‑suspicion cases → consider <strong>re‑testing</strong> with expanded panels or repeat surveillance per guidelines.  </li>
<li style="margin-left: 0px;">VUS → periodic re‑evaluation as databases update; may trigger functional studies.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>8. Risk Prediction Tools &amp; Clinical Decision Support  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>8.1 Predictive Models for LS  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Model</th>
<th>Input Variables</th>
<th>Output</th>
</tr></thead>
<tbody>
<tr>
<td><strong>PREMM 1,2,6</strong></td>
<td>Personal/family cancer history (CRC, endometrial, ovarian, gastric, etc.)</td>
<td>Probability of pathogenic MMR/EPCAM mutation</td>
</tr>
<tr>
<td><strong>MMRpro</strong></td>
<td>Detailed pedigree, tumor MSI/IHC results</td>
<td>Mutation carrier probability</td>
</tr>
<tr>
<td><strong>MMRpredict</strong></td>
<td>Age at diagnosis, tumor location, MSI status</td>
<td>Likelihood of LS gene mutation</td>
</tr>
</tbody>
</table>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Thresholds (e.g., ≥5 % PREMM risk) trigger germline testing per NCCN.  </li>
</ul>
</div></details>
<details><summary><strong>8.2 Decision Algorithms for Surveillance Intervals  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Spigelman scoring</strong> (duodenal adenomas): points → surveillance interval (0:4 y, I:2‑3 y, II:1‑3 y, III:6‑12 m, IV:3‑6 m + surgical eval).  </li>
<li style="margin-left: 0px;"><strong>Colorectal polyp burden</strong> in FAP/AFAP/MAP: &gt;20 adenomas → consider colectomy; ≤20 → endoscopic control with 6‑12 m colonoscopy.  </li>
</ul>
</div></details>
<details><summary><strong>8.3 Integration into Electronic Health Records (EHR)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Automated alerts for <strong>age‑specific screening initiation</strong> based on genotype.  </li>
<li style="margin-left: 0px;">Clinical pathways embed <strong>chemoprevention eligibility</strong> (e.g., aspirin recommendation for LS carriers &gt;50 y).  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>9. Multidisciplinary Management Framework  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>9.1 Core Team Members  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Gastroenterologist (endoscopic surveillance)  </li>
<li style="margin-left: 0px;">Surgical oncologist / colorectal surgeon (colectomy, IPAA/IRA decisions)  </li>
<li style="margin-left: 0px;">Medical oncologist (chemoprevention, systemic therapy for extra‑colonic cancers)  </li>
<li style="margin-left: 0px;">Genetic counselor / medical geneticist (testing, family communication)  </li>
<li style="margin-left: 0px;">Gynecologic oncologist (endometrial/ovarian surveillance, prophylactic surgery)  </li>
<li style="margin-left: 0px;">Radiologist (MRI/EUS for pancreatic, small bowel imaging)  </li>
<li style="margin-left: 0px;">Dermatologist (desmoid, cutaneous manifestations)  </li>
</ul>
</div></details>
<details><summary><strong>9.2 Care Coordination Pathway  </strong></summary><div style="padding-left: 20px;">
<p>1. <strong>Initial referral</strong> → genetics clinic for pedigree &amp; testing.</p>
<p>2. <strong>Result disclosure</strong> → genotype‑driven surveillance schedule entered into EHR.</p>
<p>3. <strong>Annual multidisciplinary tumor board</strong> reviews:</p>
<ul style="list-style-type: disc;">
<li style="margin-left: 30px;">Surveillance findings (polyp burden, dysplasia).  </li>
<li style="margin-left: 30px;">Need for surgical intervention or chemoprevention adjustment.  </li>
<li style="margin-left: 30px;">Emerging extra‑colonic lesions (e.g., pancreatic cysts).  </li>
</ul>
<p>4. <strong>Patient education portal</strong> provides personalized reminders for colonoscopy, imaging, and medication adherence.</p>
</div></details>
<details><summary><strong>9.3 Psychosocial &amp; Reproductive Counseling  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Discuss <strong>fertility preservation</strong>, especially before prophylactic hysterectomy or colectomy in young women.  </li>
<li style="margin-left: 0px;">Offer <strong>psychological support</strong> for anxiety related to cancer risk and surveillance burden.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>10. Chemoprevention Summary Across Syndromes  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Syndrome</th>
<th>Agent(s)</th>
<th>Dose / Regimen</th>
<th>Evidence Level</th>
<th>Key Outcomes</th>
</tr></thead>
<tbody>
<tr>
<td>LS</td>
<td>Aspirin (low‑dose 81 mg or standard 300‑600 mg)</td>
<td>Daily, ≥2 y</td>
<td>CAPP2 RCT (HR 0.25 for CRC)</td>
<td>↓ CRC incidence; dose–response unclear</td>
</tr>
<tr>
<td>FAP</td>
<td>Sulindac 150 mg BID</td>
<td>Continuous; effect wanes after stop</td>
<td>Giardiello et al., multiple trials</td>
<td>↓ adenoma count &amp; size (~56‑65 %); recurrence on cessation</td>
</tr>
<tr>
<td>FAP</td>
<td>Celecoxib 400 mg BID (high dose)</td>
<td>Limited use; FDA indication withdrawn</td>
<td>RCTs show adenoma regression at high dose</td>
<td>↑ cardiovascular risk; not recommended</td>
</tr>
<tr>
<td>MAP</td>
<td>NSAIDs (Sulindac)</td>
<td>Variable; limited data</td>
<td>Small cohort studies</td>
<td>Modest ↓ adenomas; insufficient for guideline recommendation</td>
</tr>
<tr>
<td>PJS, JPS, SPS</td>
<td>No proven chemopreventive agents</td>
<td>–</td>
<td>–</td>
<td>Surveillance remains primary strategy</td>
</tr>
</tbody>
</table>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Adverse effects</strong>: aspirin → GI bleed, hemorrhagic stroke; NSAIDs → renal dysfunction, cardiovascular events.  </li>
</ul>
</div></details>
<details><summary><strong>11. Emerging Research &amp; Future Directions  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>11.1 Next‑Generation Sequencing Panels  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Broad panels (≥30 genes) increase detection of atypical or overlapping syndromes but raise <strong>VUS</strong> burden.  </li>
<li style="margin-left: 0px;">Need for standardized reporting frameworks and functional assays to reclassify VUS.  </li>
</ul>
</div></details>
<details><summary><strong>11.2 High‑Definition Endoscopy &amp; AI‑Assisted Polyp Detection  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Chromoendoscopy, narrow‑band imaging (NBI), and high‑definition colonoscopes improve adenoma detection in LS; ongoing trials evaluating impact on interval cancer rates.  </li>
</ul>
</div></details>
<details><summary><strong>11.3 Immunoprevention &amp; Vaccines  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Investigational <strong>MMR peptide vaccines</strong> aim to boost immune surveillance in LS carriers; early phase studies show immunogenicity but clinical efficacy pending.  </li>
</ul>
</div></details>
<details><summary><strong>11.4 Personalized Chemoprevention  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Pharmacogenomic profiling (e.g., CYP2C9, UGT1A6 variants) may predict aspirin metabolism and bleeding risk, guiding individualized dosing.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>12. Consolidated Clinical Algorithm (High‑Level)  </strong></summary><div style="padding-left: 20px;">
<p>1. <strong>Identify high‑risk individual</strong> → apply Amsterdam/Bethesda criteria or predictive model threshold.</p>
<p>2. <strong>Perform tumor testing</strong> (MSI/IHC). If abnormal → proceed to germline sequencing of implicated gene(s).</p>
<p>3. <strong>If pathogenic mutation confirmed:</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 30px;">Register in <strong>hereditary cancer registry</strong>; initiate genotype‑specific surveillance schedule (colon, upper GI, gynecologic, etc.).  </li>
<li style="margin-left: 30px;">Offer <strong>genetic counseling</strong> for patient &amp; relatives; cascade testing.  </li>
<li style="margin-left: 30px;">Discuss <strong>chemoprevention</strong> (aspirin for LS) and lifestyle modifications (smoking cessation, BMI control).  </li>
</ul>
<p>4. <strong>If no mutation detected but clinical suspicion remains:</strong></p>
<ul style="list-style-type: disc;">
<li style="margin-left: 30px;">Consider multi‑gene panel or repeat testing after 2–3 y.  </li>
<li style="margin-left: 30px;">Continue surveillance per highest‑risk phenotype (e.g., FAP‑like colonoscopy intervals).  </li>
</ul>
<p>5. <strong>Reassess annually</strong> in multidisciplinary tumor board; adjust surveillance, surgical timing, and chemoprevention based on evolving data and patient preferences.</p>
<p><em>End of Part 3 – covering genetic counseling, risk prediction tools, multidisciplinary care pathways, chemoprevention across syndromes, emerging research, and a consolidated management algorithm.</em></p>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
